Clinician-facing confidence signal. Not the confidence score. The decision about how the model communicates its uncertainty to the clinician, in language and at a granularity that lets the clinician calibrate when to override. A 0.87 confidence number is useless. A signal that says "this output is in a region where the model has historically had a 12% override rate at your institution" is calibration. Confidence signaling is where most clinical-adjacent AI quietly fails. The model may be 90% accurate, but if the signal trains the clinician to trust it on the 10% where it fails, deployment is worse than no model at all.
What "co-authored from day 1" actually looks like
Co-authored from day 1 doesn't mean compliance attends the kickoff. It means the eval-harness ownership, the audit-boundary scope, the rollback authority, and the confidence-signal vocabulary are decided before the model is selected. The model is selected partly on which models can satisfy those four primitives, not just on raw accuracy.
In practice, this looks like a four-way decision-record signed at week one:
- The eval harness owner is named (a specific person, not "the platform team")
- The audit boundary is scoped (specific decision granularity, retention period, evidence schema)
- The rollback path is authored (named authority, named mechanism, named fallback)
- The confidence-signal vocabulary is sketched (what the clinician sees, not the raw probability)
The decision-record exists before any model is procured. It is signed by AI, compliance, clinical leadership, and engineering. It is updated when load-bearing decisions change. The decision-record is the artifact that distinguishes design-input governance from review-end governance.
Three signs your program is design-input, not review-end
Compliance can answer "what would a rollback look like?" without consulting engineering. If compliance has to ask, rollback is engineering-owned, which means it's review-end.
Clinical leadership has approved the confidence-signal vocabulary, not the confidence-score format. If clinical leadership signed off on "we'll surface a 0-1 confidence value," that's signal-as-checkbox. Calibration is a vocabulary question, not a numeric-range question.
The eval harness is running against last quarter's input distribution, not last year's validation set. If the harness hasn't been updated since model selection, it's not a harness. It's a snapshot.
Programs failing all three are review-end. Programs passing all three have the design-input discipline that ships clinical-adjacent AI at scale.
Why this matters now
Two pressures are converging. Regulatory: the AI-governance posture that was sufficient for cloud-era enterprise software is not sufficient for clinical-adjacent AI. Auditors are starting to ask design-input questions, not review-end questions. Programs without design-input artifacts are going to discover this expensively. Operational: as model capability plateaus and converges across vendors, the structural advantage in health-payer-scale AI shifts to the orgs with the harness, audit, and rollback discipline to deploy any model safely. The parallel in regulated legal work is the AI governance infrastructure that policy alone can't catch, where the prevention lives in the pipeline, not the policy document. The differentiator stops being which model and starts being which infrastructure.
The retrofit programs build impressive demos. The design-input programs build production systems. The difference is not which models you select. It is what you decide before the models are selected, and who owns each decision when reality changes.
Related reading